For research use only. Not for human or animal consumption.
What it is
Thymosin Alpha-1 (thymalfasin, Tα1) is a 28-amino-acid polypeptide. Its sequence corresponds to residues 2–29 of the precursor protein prothymosin alpha (UniProt P06454), and the N-terminal serine carries an Nα-acetyl group — UniProt annotates that residue as “N-acetylserine; in Prothymosin alpha, N-terminally processed”. The acetyl group is part of the molecule’s definition, not a decoration on it.
The identifiers a genuine vial and its certificate should both match:
- Chemical name: Thymosin Alpha-1 (thymalfasin, Tα1)
- CAS number: 62304-98-7
- Molecular formula: C129H215N33O55
- Molecular weight: 3108.32 (free base)
- Form: lyophilised powder
- Storage: −20 °C, desiccated, protected from light
- Release specification: >99% by HPLC main peak; identity by mass spectrometry
PubChem CID 16130571 independently returns the same formula and a mass of 3108.3, and its canonical records the acetylated form (thymalfasin) as its own entry, distinct from the unacetylated peptide.
One physical fact matters for bench planning: Nepravishta et al. reported the peptide intrinsically unstructured in aqueous solution, with no stable secondary structure in water, and observed a helical conformation only on contact with a membrane mimic. [2]
What researchers are studying
A PubMed query for “thymosin alpha 1” returned 864 records on 2026-08-20, so this literature is not thin — but most of that volume sits in clinical work, which is not described here. What follows is the preclinical, analytical and biophysical portion.
- Analytical speciation of thymosin proteoforms. Cabras et al. used HPLC coupled to high-resolution Orbitrap mass spectrometry to detect alpha and beta thymosins across tissues and bodily fluids, and reported the resolution of truncated variants, sulfoxide derivatives and acetylated forms. The authors state the origin and significance of these proteoforms remains to be investigated. [1]
- Conformational behaviour at membrane interfaces. Nepravishta et al. used NMR and circular dichroism, with paramagnetic relaxation measurements, to examine folding against sodium dodecyl sulfate micelles as a model membrane. They reported the peptide unstructured in aqueous solution, with residues 1–5 inserting into the hydrophobic region on contact. [2]
- Nα-acetylation as a defined structural feature. Chen et al. acetylated a Tα1–human serum albumin fusion expressed in yeast in vitro using purified RimJ acetyltransferase, confirmed the modification by mass spectrometry, and measured stronger binding of the enzyme to the unacetylated form. [3]
- Macrophage polarization state during efferocytosis. Wei et al. measured macrophage polarization state in cell culture and in a murine tumour model, and described SHIP1 activation via the lysosomal TLR7/MyD88 pathway with IL10 production as the proposed molecular route. No human subjects. [4]
- A documented replication failure. Six independent laboratories ran a coordinated re-test, in cellular models, of an earlier report on F508del-CFTR protein maturation and channel activity. They reported that they could not reproduce those findings. [5]
- Proposed mode of action, reviewed. A review surveys preclinical and clinical reports, including Toll-like receptor activation in dendritic cells and observations on immune cell subsets. Both authors write under a declared SciClone Pharmaceuticals interest — SciClone markets the pharmaceutical form of the peptide — which is a reason to weight primary data above review summary. [6]
Each item above describes what has been studied, and in what system: a mass spectrometer, a micelle, a cell line, a mouse. None of it describes an outcome in a person. The 2019 replication attempt [5] is listed deliberately: a negative finding is part of the honest record of a compound.
How to verify a vial of thymosin-alpha-1 before you pay
The certificate for the lot currently listed against this product was issued by Freedom Diagnostics Testing. Clarion works with more than one outside laboratory, and each lot’s certificate names the laboratory that ran it — so every check below runs against that document, not a vendor’s claim.
- Read the mass-spectrometry trace, not only the HPLC number. This is the check specific to this molecule. A des-acetyl 28-mer has the identical amino-acid sequence, elutes as a clean single main peak, and satisfies a “>99% by HPLC main peak” specification while being a different compound — 42 Da lighter, the mass of C2H2O. Chromatography cannot settle that question; the mass number can. Cabras et al. made the point directly: they resolved acetylated, truncated and sulfoxide thymosin proteoforms by high-resolution MS rather than by chromatography alone. [1]
- Match the identifiers to the molecule. CAS 62304-98-7, formula C129H215N33O55, mass 3108.32. That rules out the neighbouring “thymic” peptides sold alongside it: Thymosin Beta-4 and its Ac-LKKTETQ fragment sold as TB-500 (C38H68N10O14, MW 889.01, CAS 885340-08-9), thymulin (a zinc-binding nonapeptide) and thymopentin (a five-residue thymopoietin fragment). A trade name on a label does not discriminate between them; the CAS number and the mass do.
- Match the lot. The lot you received must be the lot printed on the certificate; a certificate for a different batch says nothing about the vial in hand.
- Ask what the purity figure was measured against. MW 3108.32 is the free base. A vial filled by weight also carries residual counterions from reverse-phase purification — Tα1 offers four lysine side chains to bind them — plus water of hydration. Net peptide content is a separate determination (amino-acid analysis, nitrogen determination, quantitative NMR) from HPLC main-peak area, so two vials with the same stated purity can hold different masses of peptide.
A final point follows from the biophysics. Nepravishta et al. reported the peptide unstructured in water, folding only against a membrane mimic [2], so there is no conformational signature to observe once the powder is in solution: how the solution looks or behaves carries no identity information. Identity here is settled on the dry powder, by HPLC and mass spectrometry, before the vial is filled — or it is not settled at all.
Both documents are public. The lot ledger resolves a lot number to that lot’s own signed third-party certificate, also linked from the Thymosin Alpha-1 product page. The
Common questions
What is Thymosin Alpha-1, in one line? A 28-amino-acid polypeptide (CAS 62304-98-7, MW 3108.32) corresponding to residues 2–29 of prothymosin alpha, supplied as a lyophilised powder for research use only.
Why is the acetyl group singled out? Because it is the identity question HPLC cannot answer. The des-acetyl form has the same sequence, the same chromatographic behaviour and a different mass. Only the MS identity data on the certificate separates the two. [1]
Is Thymosin Alpha-1 the same as TB-500 or thymulin? No. TB-500 is an Ac-LKKTETQ fragment of Thymosin Beta-4 (C38H68N10O14, MW 889.01); thymulin is a zinc-binding nonapeptide. Different molecules, different masses, different CAS numbers.
Which laboratory tested it? For the lot currently listed against this product, Freedom Diagnostics Testing. The laboratory is named on each lot’s certificate rather than assumed across the catalogue.
How is it stored? At −20 °C, desiccated and protected from light, as a lyophilised powder.
Is this a medicine? No. It is a research-use-only material, not for human or animal consumption.
References
- Cabras T, Iavarone F, Martelli C, et al. **High-resolution mass spectrometry for thymosins detection and characterization.* *Expert Opin Biol Ther. 2015;15(Suppl 1):S191–201. PMID: 26095945. DOI: 10.1517/14712598.2015.1009887.
- Nepravishta R, Mandaliti W, Eliseo T, et al. **Thymosin α1 inserts N terminus into model membranes assuming a helical conformation.* *Expert Opin Biol Ther. 2015;15(Suppl 1):S71–81. PMID: 25642593. DOI: 10.1517/14712598.2015.1009034.
- Chen J, Li H, Wang T, et al. **Production of N(α)-acetyl Tα1-HSA through in vitro acetylation by RimJ.* *Oncotarget. 2017;8(56):95247–95255. PMID: 29221124. DOI: 10.18632/oncotarget.20259.
- Wei YT, Wang XR, Yan C, et al. 2022;82(10):1991–2002. PMID: 35364609. DOI: 10.1158/0008-5472.CAN-21-4260. Subject: macrophage polarization state during efferocytosis, in cell culture and a murine model. (Published title and journal name are not reproduced here; both carry vocabulary this page does not use. Retrieve them from the PMID or DOI above.)
- Armirotti A, Tomati V, Matthes E, et al. **Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity.* *Sci Rep. 2019;9(1):10310. PMID: 31311979. DOI: 10.1038/s41598-019-46639-1.
- King R, Tuthill C. Vitam Horm. 2016;102:151–178. PMID: 27450734. DOI: 10.1016/bs.vh.2016.04.003. Subject: a review of the proposed mode of action. (Published title is not reproduced here; it carries vocabulary this page does not use. Review article; both authors write under a declared SciClone Pharmaceuticals interest.)
Chemistry identifiers cross-checked against UniProt P06454 and PubChem CID 16130571.
Related: How to verify a peptide certificate of analysis.
Thymosin Alpha-1 (thymalfasin, Tα1), CAS 62304-98-7, C129H215N33O55, MW 3108.32. Released to a >99% HPLC main-peak specification with identity confirmed by mass spectrometry; the certificate for each lot names the laboratory that ran it and is reachable from the lot ledger or the QR code on the certificate card that ships with the vials. For research use only. Not for human or animal consumption. Not a drug.
